Cyxone AB (CYXO) NPV
0.006 SEK
(20.34%)
- Add to watchlist
- This stock can be held in a
0.006 SEK
(20.34%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
0.006 SEK
(20.34%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Cyxone AB is a Sweden-based company, which is primarily focused on specialty pharmaceuticals industry. The Company develops cyclotide drugs for autoimmune and other diseases. The Company's Product T20K is a compound to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. The product T20K, through a pre-clinical program required for clinical studies in multiple sclerosis. The Company's cyclotides technology can be modified, while keeping the core cyclotide drug structure, to introduce a variety of pharmaceutical properties for selected diseases. The Company has acquired the cyclotide patent rights developed by the Medical University of Vienna and the University Medical Center of Freiburg.
Contact details
Important dates
General stock information
- Short code:
- CYXO
- ISIN:
- SE0007815428
- Market cap:
- 11.06 million SEK
- Shares in issue:
- 791.73 million
- Sector:
- Biotechnology
- Exchange:
- Stockholm Stock Exchange
- Country:
- Sweden
- Currency:
- Swedish Krona
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.